3478-09-9

Basic information

• Product Name: 3-methyl-2,6-dinitrobenzoic acid
• Synonyms: 3-methyl-2,6-dinitrobenzoic acid
• CAS NO: 3478-09-9
• Molecular Weight: 226.145
• Mol File: 3478-09-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 174-178 °C
• Boiling Point: 408.0±45.0 °C(Predicted)
• Density: 1.593±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-methyl-2,6-dinitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-2,6-dinitrobenzoic acid(3478-09-9)
• EPA Substance Registry System: 3-methyl-2,6-dinitrobenzoic acid(3478-09-9)

Safety Data

• Hazardous Substances Data: 3478-09-9(Hazardous Substances Data)

Upstream product

• 99-04-7 m-Toluic acid 
• 64-17-5 ethanol 
• 5437-38-7 3-methyl-2-nitrobenzoic acid 

Downstream Products

• 90001-60-8 2,6-Dinitro-3-methyl-benzoylchlorid 
• 873055-34-6 3-(2-dimethylamino-vinyl)-2,6-dinitro-benzoic acid ethyl ester 
• 103041-13-0 3-methyl-2,6-dinitrobenzoic acid ethyl ester 
• 174311-78-5 (E)-3-<2-(dimethylamino)ethenyl>-2,6-dinitrobenzoic acid ethyl ester 
• 174311-79-6 6-amino-1H-indole-7-carboxylic acid ethyl ester 
• 83807-18-5 2,6-Dinitro-3-methyl-benzoesaeure-methylester 
• 27715-65-7 2,6-Dinitro-3-methyl-benzamid 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.